BTK and B-cell chronic lymphocytic leukemia: Ibrutinib, an irreversible BTK inhibitor, was initially approved for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) (Hendriks et al., 2014).